Literature DB >> 3978627

Effects of clumps and clusters on survival measurements with clonogenic assays.

S Rockwell.   

Abstract

The growth of colonies in semisolid medium is receiving widespread attention as a possible test for predicting the clinical response of individual human tumors to specific drugs. One problem encountered in these studies is the difficulty of preparing single-cell suspensions from solid tumors. Often, microscopic examination of the cultures just after plating reveals many clusters or clumps of cells; these are often large enough and numerous enough that some plates are counted or fixed immediately so that this "background" can be subtracted from the "colony" count used to assess cell viability. However, this correction addresses only one of the problems created by the presence of clumps and clusters. It does not eliminate errors and artifacts introduced by multiplicity (multiple clonogenic cells contributing to a colony), abortive clones, and cell volume changes, or by inhomogeneities in the microenvironment, cell metabolism, and drug distribution within clumps. Because of such factors, survival curves determined using suspensions contaminated with clumps and clusters may provide inaccurate assessments of the true drug sensitivity of the individual tumor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978627

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Clonal growth of bladder cancer cells in a double layer soft agar assay: needles addition of multiple culture supplements.

Authors:  K Lee; P Smith; G H Weiss; A T Cockett
Journal:  Urol Res       Date:  1990

2.  An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tumour necrosis factor.

Authors:  G Unsgaard; E Helseth; R Vik; A Dalen
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

3.  Effects of hormonal growth factors on colony formation and chemosensitivity of human tumors in agarose.

Authors:  D H Kern; F W Chien; S N Goodwein; V K Sondak
Journal:  In Vitro Cell Dev Biol       Date:  1987-12

4.  Direct and indirect effects of human interferon alpha on renal cell carcinoma: a new in vitro assay system for evaluating cytokine-mediated antitumor effects.

Authors:  H Matsuyama; S Yoshihiro; Y Ohmoto; N Yamamoto; K Naito
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

5.  Experiences with the human tumor colony-forming assay in gynecologic malignancies.

Authors:  G E Umbach; J Poethen; H von Matthiessen; H G Bender; U Koldovsky
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

6.  The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution.

Authors:  Frédérique Mégnin-Chanet; François Lavelle; Vincent Favaudon
Journal:  BMC Pharmacol       Date:  2002-02-06

7.  Lack of a correlation between micronucleus formation and radiosensitivity in established and primary cultures of human tumours.

Authors:  R Villa; N Zaffaroni; D Gornati; A Costa; R Silvestrini
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

8.  PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility.

Authors:  Camille Godon; Fabrice P Cordelières; Denis Biard; Nicole Giocanti; Frédérique Mégnin-Chanet; Janet Hall; Vincent Favaudon
Journal:  Nucleic Acids Res       Date:  2008-07-04       Impact factor: 16.971

9.  Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro.

Authors:  N Giocanti; C Hennequin; D Rouillard; R Defrance; V Favaudon
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.